| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.4 | 1.2 |
| Net income | -1.4 | -2.0 |
| EPS (diluted, $ a share) | $-0.04 | $-0.06 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -61.4% |
|---|---|
| Operating margin | -403.6% |
10-Q filed with the SEC, NASDAQ: DYAI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dyadic International Inc: key numbers
- Share price
- $0.3200Close, Nov 16
- Market cap
- $12.8M
- Shares outstanding
- 40.09MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dyadic International Inc
All →Dyadic International Earnings Call: Key Takeaways
Dyadic is transitioning to a commercial-stage company with modest initial sales, but faces liquidity constraints and slower-than-expected customer adoption despite technical validation from the Gates Foundation and partners.
- Call
- Nov 12, 2026, 5:00 PM ET
Dyadic International Financial Results
Dyadic International reported Q3 2026 financial results, highlighting its first direct commercial protein sales and expanded OEM distribution through IBT Bioservices. The company reported a net loss of $1.5M on revenue of $0.7M as it shifts focus toward larger strategic partnerships and licensing arrangements for its C1 and Dapibus production platforms.
- Term
- Q3 2026
“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors.”
Joe Hazelton, President and Chief Operating Officer
“Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs.”
Joe Hazelton, President and Chief Operating Officer
Dyadic International Nasdaq/NYSE Compliance Notice
Dyadic International received two deficiency notices from Nasdaq for failing to maintain a minimum bid price of $1.00 per share and a minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance with both requirements.
- Counterparty
- The Nasdaq Stock Market LLC
- Term
- 180 days